You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Robust Antitumor Activity and Low Cytokine Production by Novel Humanized Anti-CD19 CAR T CellsAnti-CD19 CAR with Favorable Efficacy to Toxicity Balance
|
|---|---|
| Published in |
Molecular Cancer Therapeutics, February 2021
|
| DOI | 10.1158/1535-7163.mct-20-0476 |
| Pubmed ID | |
| Authors |
Alka Dwivedi, Atharva Karulkar, Sarbari Ghosh, Srisathya Srinivasan, Bajarang Vasant Kumbhar, Ankesh Kumar Jaiswal, Atish Kizhakeyil, Sweety Asija, Afrin Rafiq, Sushant Kumar, Albeena Nisar, Deepali Pandit Patil, Minal Vivek Poojary, Hasmukh Jain, Shripad D. Banavali, Steven L. Highfill, David F. Stroncek, Nirali N. Shah, Terry J. Fry, Gaurav Narula, Rahul Purwar |
X Demographics
The data shown below were collected from the profiles of 78 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| India | 36 | 46% |
| United States | 6 | 8% |
| Comoros | 1 | 1% |
| Russia | 1 | 1% |
| Saudi Arabia | 1 | 1% |
| Brazil | 1 | 1% |
| Unknown | 32 | 41% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 48 | 62% |
| Scientists | 14 | 18% |
| Practitioners (doctors, other healthcare professionals) | 10 | 13% |
| Science communicators (journalists, bloggers, editors) | 6 | 8% |
Mendeley readers
The data shown below were compiled from readership statistics for 30 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 30 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 4 | 13% |
| Researcher | 3 | 10% |
| Student > Bachelor | 2 | 7% |
| Unspecified | 2 | 7% |
| Student > Master | 2 | 7% |
| Other | 3 | 10% |
| Unknown | 14 | 47% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 23% |
| Unspecified | 2 | 7% |
| Biochemistry, Genetics and Molecular Biology | 2 | 7% |
| Immunology and Microbiology | 2 | 7% |
| Agricultural and Biological Sciences | 1 | 3% |
| Other | 2 | 7% |
| Unknown | 14 | 47% |
Attention Score in Context
This research output has an Altmetric Attention Score of 84. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 March 2024.
All research outputs
#516,493
of 25,775,807 outputs
Outputs from Molecular Cancer Therapeutics
#54
of 4,092 outputs
Outputs of similar age
#15,290
of 454,290 outputs
Outputs of similar age from Molecular Cancer Therapeutics
#1
of 68 outputs
Altmetric has tracked 25,775,807 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,092 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.9. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 454,290 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 68 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.